TuHURA Biosciences Stock (NASDAQ:HURA)


OwnershipFinancialsChart

Previous Close

$2.29

52W Range

$0.41 - $4.20

50D Avg

$1.90

200D Avg

$1.95

Market Cap

$149.41M

Avg Vol (3M)

$1.98M

Beta

-0.32

Div Yield

-

HURA Company Profile


TuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, FL.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

19

IPO Date

Feb 22, 2013

Website

HURA Performance


HURA Financial Summary


Dec 25Dec 24Dec 23
Revenue---
Operating Income-$-17.65M$-29.76M
Net Income$-30.06M$-21.68M$-29.32M
EBITDA-$-17.43M$-29.12M
Basic EPS$-0.63$-1.21$-11.29
Diluted EPS$-0.63$-1.21$-11.29

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison


TickerCompany
IRDOpus Genetics, Inc.
SPROSpero Therapeutics, Inc.
TVGNTevogen Bio Holdings Inc.
AGENAgenus Inc.
SEERSeer, Inc.
INOInovio Pharmaceuticals, Inc.
VTGNVistaGen Therapeutics, Inc.
CGTXCognition Therapeutics, Inc.
MCRBSeres Therapeutics, Inc.
ABOSAcumen Pharmaceuticals, Inc.